Breaking News

Ex-Prometheus Executives Launch Mirador Therapeutics

Aims to revolutionize precision medicine for immune-mediated inflammatory and fibroitic diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Mirador Therapeutics Inc., founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences, launched today with the goal of revolutionizing precision medicine for immune-mediated inflammatory and fibroitic diseases by leveraging its proprietary Mirador360 development engine to rapidly advance multiple programs.   Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other investors inclu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters